NCT00164281

Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana

A Randomized, Placebo-Controlled Study of Limited vs. Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 2,000 (actual)
• Sponsor: Centers for Disease Control and Prevention · Federal
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, blinded, two-arm comparative trial of continued versus limited isoniazid (INH) tuberculosis (TB) preventive therapy in HIV-infected adults in Gaborone and Francistown, Botswana. Subjects will be accrued over two years and followed for a minimum of 36 months.

Detailed description

Randomized, double blinded, two-arm comparative trial of continuous vs. limited isoniazid preventive therapy in HIV-infected adults in Gaborone and Francistown, Botswana. Subjects will be accrued over two years and followed for a minimum of 36 months.

Conditions

• Tuberculosis
• HIV Infections

Interventions

Type	Name	Description
DRUG	Isoniazid	Daily 300 mg isoniazid supplemented with 25 mg pyridoxine for 6 months vs 36 months.

Timeline

• Start date: 2004-11-01
• Primary completion: 2009-07-01
• Completion: 2011-05-01
• First posted: 2005-09-14
• Last updated: 2014-02-06

Locations

1 site across 1 country: Botswana